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operated tumor, node, metastasis 
Stage II NSCLC patients. Therefore, 
an effective secondary prevention is 
imperative in these patients to ensure 
the best outcomes.
Notwithstanding, it has been 
shown that lung cancer patients often 
receive a higher dose of radiation 
with conventional-dose CT than that 
considered safe, which could increase 
significantly their already increased 
lifetime cancer risk.4 As a result, strate-
gies are stringently needed to decrease 
radiation doses during the postopera-
tive follow-up in these patients, the 
majority of whom will never relapse. 
Given the results of NLST, it seems 
that utility of low-dose CT should 
also be tested in these patients who 
have completed curative treatment, 
but who remain at increased risk for 
recurrent disease. Further studies of 
the underlying economic, psychoso-
cial, and physical barriers of low-dose 
CT in this population are probably 
warranted.
Constantin A. Dasanu, MD, PhD
Department of Hematology-oncology 
St. Francis Hospital and Medical Center 
Hartford, CT
Ion Codreanu, MD, PhD
Department of Radiology 
The University of Arizona 
Medical Center 
Tucson, AZ
REFERENCES
 1. Field JK, Smith RA, Aberle DR, et al.; IASLC 
CT Screening Workshop 2011 Participants. 
International Association for the Study 
of Lung Cancer Computed Tomography 
Screening Workshop 2011 report. J Thorac 
Oncol 2012;7:10–19.
 2. Aberle DR, Adams AM, Berg CD, et al.; 
National Lung Screening Trial Research 
Team. Reduced lung-cancer mortality with 
low-dose computed tomographic screening. 
N Engl J Med 2011;365:395–409.
 3. Gauger J, Patz EF Jr, Coleman RE, Herndon 
JE 2nd. Clinical stage I non-small cell lung 
cancer including FDG-PET Imaging: sites 
and time to recurrence. J Thorac Oncol 
2007;2:499–505.
 4. Stiles BM, Mirza F, Towe CW, et al. 
Cumulative radiation dose from medical 
imaging procedures in patients undergoing 
resection for lung cancer. Ann Thorac Surg 
2011;92:1170–1178; discussion 1178.
Induction 
Chemotherapy 
Inevitably Leads to 
Inferior Outcome in 
Combined Modality 
Treatment for 
Unresectable Stage III 
Non-small Cell  
Lung Cancer
To the Editor:
We read with interest the recent 
retrospective report of Chen et al.1 on the 
deleterious effects of delayed initiation 
of radiotherapy (RT) after induction che-
motherapy (CHT) in stage III non-small 
cell lung cancer (NSCLC) due to tumor 
regrowth occurring within a few weeks. 
They have concluded that RT treat-
ment planning should begin as soon as 
possible after the administration of induc-
tion CHT to maximize its benefits and 
provided a volumetric analysis of tumors 
to support their conclusion of acceler-
ated repopulation as the mechanism for 
regrowth during delays. Their results in 
fact reconfirm the study of El-Sharouni 
et al.2 which compared computed tomog-
raphy (CT) scans-based assessment of 
tumor changes before and after induction 
CHT, with an emphasis on the time inter-
val from the last induction CHT cycle 
to the timing of the RT treatment plan-
ning CT scan. They showed that during 
the waiting period (for the planning CT 
scan and start of RT), a total of 41% of all 
tumors became incurable. Bozcuk et al.3 
recently looked at the benefits of induc-
tion CHT before RT in NSCLC using 
a meta-analytical approach with meta-
regression analysis. Using 13 completed 
randomized clinical trials involving a total 
of 2776 patients, they found that the time 
to RT initiation was inversely associated 
with the benefit from induction CHT at 2 
( p = 0.050) and 3 years ( p = 0.093).
As noted by the authors, a range 
of prospective randomized clinical tri-
als followed by recent meta-analyses4 
have confirmed that in unresectable 
stage III NSCLC patients meeting the 
selection criteria for such trials, the 
standard of care is concurrent RT-CHT, 
with CHT initiated on day 1 of RT, as 
compared with sequential CHT fol-
lowed by RT. Furthermore, the recently 
published randomized trial (CALGB 
39801)5 of concurrent RT-CHT with or 
without the addition of induction CHT 
showed that the experimental arm gen-
erated excess toxicity and provided 
no survival benefit over concurrent 
RT-CHT alone.5 With this evidence in 
mind, the present report by Chen et al. 
fails to adequately justify their con-
clusion about future clinical research 
in this setting without clear upfront 
patient and/or tumor selection criteria 
which may prompt an indication for 
the use of induction CHT. In addition, 
they identify “logistical/scheduling 
constraints in 14 of 21 cases” which 
are otherwise not characterized as the 
basis for delays in RT initiation after 
induction. This suggests a number of 
variables in their study population 
which would not conventionally make 
these patients trial eligible. Without 
better character ization of their popula-
tion, it then becomes difficult to under-
stand why one should optimize what 
is already an inferior (i.e., induction 
CHT) approach to managing stage III 
NSCLC but not further optimize the 
better (RT-CHT) approach associated 
with the optimal survival.
We share the authors’ goals in pro-
viding the best care possible for patients 
confronting locally advanced lung can-
cer and agree that optimizing the deliv-
ery of RT is a priority. The old notion of 
“doing something while the patient waits 
for the radiotherapy planning scan” is 
clearly not tenable. A more detailed 
analysis of the clinical circumstances 
in the present series would have further 
served to justify that proposition.
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One Size Does Not 
Fit All Lung Cancer 
Patients
In Response:
We thank Drs. Jeremic and Videtic 
for highlighting points related to our arti-
cle.1 We concur that the standard of care 
for eligible patients with unresectable 
stage III non–small-cell lung cancer is 
concurrent chemoradiation, as proven in 
phase III randomized trials. In our intro-
duction, we described our study rationale. 
For patients who have poor performance 
status, unduly large radiotherapy fields, 
or medical comorbidities that make 
upfront chemoradiation unrealistic or 
even risky, sequential chemoradiother-
apy is an alternative that is preferable to 
radiotherapy alone.2 It is understood that 
these patients represent a different popu-
lation than that represented in concurrent 
chemoradiation trials.
There is a request for justification 
for future clinical research. However, 
we are not proposing more prospective 
studies of induction-chemotherapy strat-
egies. This was neither the goal nor the 
main point of our study. Nonetheless, 
as the issue has now been raised, it is 
worth mentioning that the question 
of induction chemotherapy has not 
been entirely settled for poor-prognosis 
patients. A randomized phase II study, 
Locally Advanced Multi-Modality 
Protocol, included an arm of induc-
tion carboplatin/paclitaxel followed by 
concurrent chemoradiation. The induc-
tion arm produced lower median survival, 
but more patients with low Karnofsky 
performance status, male sex, and weight 
loss received induction; in addition, the 
trial accrued slowly and closed early.3 
The cancer and leukemia group B 39801 
phase III study randomized patients to 
either two cycles of carboplatin/pacli-
taxel followed by concurrent chemoradi-
ation versus concurrent chemoradiation 
alone. The median overall survival was 
longer in the induction arm (14 months 
versus 12 months), but this difference 
was not statistically significant, and both 
arms underperformed relative to histori-
cal controls. With more than 5% weight 
loss, survival was longer with induc-
tion, a finding that was not significant 
on detailed reanalysis. However, it was 
noted that prognostic factors were highly 
determinant of outcome, raising ques-
tions about the benefit of chemoradiation 
in these patients.4 None of these studies 
addressed the issue of which approach 
was to be adopted for patients unable 
to have upfront concurrent chemoradia-
tion or whose overall prognosis was so 
poor as to put the benefit of concurrent 
chemoradiation in doubt.
Regardless of what we all may 
consider optimal, many patients have 
received induction chemotherapy before 
subsequent definitive or palliative treat-
ment. We intended to present our expe-
riences with these patients who were 
treated off clinical trials. We included 
available prognostic factors and other 
variables in our study, such as patient 
demographics, performance status, and 
type of induction chemotherapy used. 
Nonetheless, we acknowledge that this 
retrospectively selected population 
sample is small and heterogeneous.
It has been estimated that as 
many as 59% of patients with locally 
advanced lung cancer are ineligible for 
concurrent chemoradiation at presenta-
tion.5 We believe there will be continued 
use of induction regimens off protocol 
for certain classes of high-risk or poor-
prognosis patients. Information from 
studies such as ours can help manage 
expectations and optimize outcomes in 
these difficult situations. We thank our 
colleagues for their interest in our work.
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